Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Asston Pharmaceuticals IPO
Price Band
₹115.0–123.0
Issue Size
₹27.56 Cr
Lot Size
1,000 shares
Min Investment
₹246,000
2 LOTS MIN
GMP
+₹26.0 (21.14%)
Issue Price
₹123.0
Subject to Sauda
₹19800
Paid only if allotted
Asston Pharmaceuticals IPO AI Summary
- Asston Pharmaceuticals IPO is listed on BSE SME in the Pharmaceuticals sector.
- Price band: ₹115.0–₹123.0 per share, lot size 1,000 shares (min. investment ₹246,000, 2 lots minimum).
- Subscription window: 09 Jul–11 Jul 2025, listing on 16 Jul 2025.
- Current GMP is +₹26.0 (21.14%), an estimated listing price of ₹149 — unofficial and can change daily.
Asston Pharmaceuticals Limited is set to enter the market with its IPO priced at ₹123.0 per share, aiming to raise ₹27.56 Cr. The company specializes in exporting healthcare products and has shown a positive trend in revenue and profit growth over the past few years. Investors should consider the company's fundamentals and market conditions when evaluating this IPO.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Asston Pharmaceuticals IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 11 Jul 2025 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Asston Pharmaceuticals IPO Grey Market Premium (GMP) Today
GMP
+₹26.0
GMP %
+21.14%
Est. Listing
₹149.0
Updated: 25 Jul 2026 14:14
About the Company
Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally. The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more. The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers. The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing. Products: Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections. Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID). Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever. Ferrovit Syrup: To treat vitamin and mineral deficiencies. As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments. Competitive Strengths: Formulation Expertise Experienced Promoters Wide range of Products Strategic Location Skilled Workforce
Company Financials (₹ Cr)
As of 2025-05-31
| Period Ended | 31 May 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 31.83 | 28.12 | 20.26 | 13.69 |
| Total Income | 6.21 | 25.61 | 15.84 | 7.19 |
| Profit After Tax | 1.32 | 4.33 | 1.36 | 1.06 |
| EBITDA | 1.93 | 6.16 | 2.55 | 1.52 |
| NET Worth | 12.04 | 10.72 | 6.39 | 1.99 |
| Reserves and Surplus | 5.77 | 4.45 | 5.61 | 1.29 |
| Total Borrowing | 7.83 | 7.26 | 6.82 | 5.25 |
Key Ratios
EPS
₹6.90
NAV
₹17.09
ROE
50.56%
ROCE
51.25%
RoNW
40.36%
P/B Value
12.07
P/E Ratio
17.83
Market Cap
₹104.70 Cr
PAT Margin
17.27%
Debt/Equity
0.68
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Trident Lifeline Ltd | 57.16 | 19.85% | 25.29 | 11.35 | 11.35 |
| BAFNA PHARMACEUTICALS Limited | 35.86 | 4.89% | 51.38 | 1.76 | 1.76 |
| Shelter Pharma Ltd | 36.96 | 16.94% | 6.7 | 6.26 | 6.26 |
| Asston Pharmaceuticals Limited This IPO | 17.09 | 40.36% | — | 6.9 | 6.9 |
Promoters
Ashish Narayan Sakalkar, Saili Jayaram More and Sachin Chandrakant Badakh
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit 6.00 2 Funding the incremental working capital requirements of the Company 13.00 3 Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company 1.00 4 General Corporate Purposes 3.95 5 Issue Expenses 3.61 Total 27.56
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹7.19 Cr in the year ending 31 Mar 2023, increasing to ₹15.84 Cr by 31 Mar 2024, and further rising to ₹25.61 Cr by 31 Mar 2025. However, the most recent figure of ₹6.21 Cr for the period ending 31 May 2025 is a 9-month figure and not directly comparable to the previous full year.
Profit Trend
Profit After Tax was ₹1.06 Cr for the year ending 31 Mar 2023, increasing to ₹1.36 Cr by 31 Mar 2024, and further rising to ₹4.33 Cr by 31 Mar 2025. The latest figure of ₹1.32 Cr for the period ending 31 May 2025 is also a 9-month figure, which makes it not directly comparable to the previous full year.
Valuation
Asston Pharmaceuticals has an implied P/E ratio of 17.83 at the issue price of ₹123.0, compared to peers trading at a P/E range of 6.7 to 51.38.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the expected listing price of an IPO compared to its issue price. A positive GMP suggests that the stock may list at a higher price than the issue price, while a negative GMP indicates the opposite. GMP is determined by demand and supply dynamics in the unregulated market.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against the company's fundamentals, market conditions, and their own investment strategy.
Who May Want to Wait
Investors with a low risk tolerance or those seeking immediate returns may want to avoid IPOs, as they can be subject to price fluctuations and market volatility.
IPO Timeline, Explained
The IPO opens for subscription on 9 July 2025 and closes on 11 July 2025. Allotment of shares is expected on 14 July 2025, with the listing date set for 16 July 2025.
Listing Gains — The Risk
Listing-day gains can be unpredictable and depend on various factors, including market sentiment, demand for the stock, and overall market conditions. Investors should be cautious, as there is no guarantee of immediate profits post-listing.
This evaluation is generated from Asston Pharmaceuticals's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Asston Pharmaceuticals IPO GMP today?
Asston Pharmaceuticals IPO GMP today is +₹26.0 (21.14%), indicating an estimated listing price of ₹149. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Asston Pharmaceuticals IPO?
The price band of Asston Pharmaceuticals IPO is ₹115.0–₹123.0 per share.
When does Asston Pharmaceuticals IPO open and close?
Asston Pharmaceuticals IPO opens on 09 July 2025 and closes on 11 July 2025.
When does Asston Pharmaceuticals IPO list on the stock exchange?
Asston Pharmaceuticals IPO listed on 16 July 2025 at ₹149.0.
What is the lot size for Asston Pharmaceuticals IPO?
The lot size for Asston Pharmaceuticals IPO is 1000 shares, requiring a minimum investment of ₹246,000 (2 lots).
What is the price band for the Asston Pharmaceuticals IPO?
The price band for the Asston Pharmaceuticals IPO is ₹115.0 to ₹123.0.
What is the minimum investment required?
The minimum investment required is ₹246,000 for a lot size of 1,000 shares.
When is the listing date for the IPO?
The listing date for the IPO is 16 July 2025.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing price of an IPO compared to its issue price.
What is the allotment date for the IPO?
The allotment date for the IPO is 14 July 2025.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
09 Jul 2025
Close
11 Jul 2025
Allotment
14 Jul 2025
Listing
16 Jul 2025
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Asston Pharmaceuticals?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.